Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Next-Generation Sequencing in Medicine (Upcoming)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Footnotes
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Corrigendum Free access | 10.1172/JCI84828

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

Deborah A. Knight, Shin Foong Ngiow, Ming Li, Tiffany Parmenter, Stephen Mok, Ashley Cass, Nicole M. Haynes, Kathryn Kinross, Hideo Yagita, Richard C. Koya, Thomas G. Graeber, Antoni Ribas, Grant A. McArthur, and Mark J. Smyth

Find articles by Knight, D. in: JCI | PubMed | Google Scholar

Find articles by Ngiow, S. in: JCI | PubMed | Google Scholar

Find articles by Li, M. in: JCI | PubMed | Google Scholar

Find articles by Parmenter, T. in: JCI | PubMed | Google Scholar

Find articles by Mok, S. in: JCI | PubMed | Google Scholar

Find articles by Cass, A. in: JCI | PubMed | Google Scholar

Find articles by Haynes, N. in: JCI | PubMed | Google Scholar

Find articles by Kinross, K. in: JCI | PubMed | Google Scholar

Find articles by Yagita, H. in: JCI | PubMed | Google Scholar

Find articles by Koya, R. in: JCI | PubMed | Google Scholar

Find articles by Graeber, T. in: JCI | PubMed | Google Scholar

Find articles by Ribas, A. in: JCI | PubMed | Google Scholar

Find articles by McArthur, G. in: JCI | PubMed | Google Scholar

Find articles by Smyth, M. in: JCI | PubMed | Google Scholar

Published November 23, 2015 - More info

Published in Volume 126, Issue 1 on January 4, 2016
J Clin Invest. 2016;126(1):402–403. https://doi.org/10.1172/JCI84828.
Copyright © 2016, American Society for Clinical Investigation
Published November 23, 2015 - Version history
View PDF

Related article:

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Deborah A. Knight, … , Grant A. McArthur, Mark J. Smyth
Deborah A. Knight, … , Grant A. McArthur, Mark J. Smyth
Corrigendum

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

  • Text
  • PDF
Abstract

Authors

Deborah A. Knight, Shin Foong Ngiow, Ming Li, Tiffany Parmenter, Stephen Mok, Ashley Cass, Nicole M. Haynes, Kathryn Kinross, Hideo Yagita, Richard C. Koya, Thomas G. Graeber, Antoni Ribas, Grant A. McArthur, Mark J. Smyth

×

Original citation: J Clin Invest. 2013;123(3):1371–1381. doi:10.1172/JCI66236.

Citation for this corrigendum: J Clin Invest. 2016;126(1):402–403. doi:10.1172/JCI84828.

An error was made during the preparation of Figure 6B, resulting in more lines on the graph than the number of samples shown. In addition, the legend for Figure 6 did not indicate that WT plus vehicle and WT plus PLX4720 samples shown in Figure 6B are also presented in Figure 6C. All samples in these panels were derived from the same set of experiments. The authors have revisited the statistical analyses to account for the number of comparisons appropriately. The corrected Figure 6 and sentences for the legend are below.

Statistical differences in tumor sizes between mice treated with vehicle and those treated with PLX4720 therapy for each group were determined by a Kruskal-Wallis test with Dunn’s correction (*P < 0.05; **P < 0.01). WT plus vehicle and WT plus PLX4720 samples shown in B are also presented in C. All samples in panels B and C were derived from the same set of experiments.

Several panels in Supplemental Figure 4 for SM1 staining were accidentally duplicated. The original raw data were reanalyzed and replotted and are shown in the updated version of the supplemental data file. The PD-L1 panel for PLX4720 10 μM was omitted in the corrected version, as there appeared to be a processing error with the original sample. The authors have stated that subsequent replicate experiments are consistent with these findings.

The egend for Supplemental Figure 9A did not indicate that the WT plus vehicle and WT plus anti-CD137 plus vehicle groups shown are presented again in Supplemental Figure 9B. The online supplemental data file has been updated to correct this issue, and the statistical analysis has been revisited to account for the number of comparisons appropriately. None of the corrections alter the conclusions of the paper.

The legend for Figure 9 did not indicate that the WT plus cIg plus vehicle and WT plus cIg plus PLX4720 groups shown are also presented in Supplemental Figure 7A. All samples in these panels were derived from the same set of experiments. The authors revisited the statistical analyses to account for the number of comparisons appropriately. Supplemental Figure 7 has been updated in the online supplemental data file. The corrected Figure 9 and sentences for the legend are shown below.

Statistical differences in tumor sizes between mice treated with anti-CD137 and those treated with combination therapy for each group were determined by a Kruskal-Wallis test with Dunn’s correction (**P < 0.01). The WT plus cIg plus vehicle and WT plus cIg plus PLX4720 groups shown are also presented in Supplemental Figure 7A. All samples in Figure 9 and Supplemental Figure 7A were derived from the same set of experiments.

The authors originally presented the same data in different panels for the sake of figure clarity and regret the subsequent confusion. The authors regret the other figure errors.

Footnotes

See the related article beginning on page 1371.

Version history
  • Version 1 (November 23, 2015): No description
  • Version 2 (January 4, 2016): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Footnotes
  • Version history
Advertisement
Advertisement

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts